Quantum Biopharma ( (TSE:QNTM) ) has shared an announcement.
On February 6, 2025, Quantum BioPharma announced that its licensee, Celly Nutrition, has engaged a leading New York investment bank to raise up to $10 million and explore an initial public offering following positive clinical results for its product, unbuzzd. This move aims to boost Celly Nutrition’s market presence and sales capabilities for unbuzzd, a beverage that accelerates alcohol metabolism and reduces hangover symptoms. The clinical trial demonstrated significant improvements in alcohol metabolism, alertness, and reduction of hangover symptoms, paving the way for expanded market opportunities.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative, metabolic, and alcohol misuse disorders. The company owns Lucid Psycheceuticals Inc., which is developing Lucid-MS, a compound for multiple sclerosis treatment. Quantum BioPharma also holds a 25.71% stake in Celly Nutrition, creator of the unbuzzd beverage, and retains rights to develop similar pharmaceutical products.
YTD Price Performance: 110.29%
Average Trading Volume: 1,713,872
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $16.83M
See more data about QNTM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com